AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-19. (Canceled)
- 20. (Currently amended) A kit for assaying free protein S, the kit comprising:
 - a ligand-selected from a group consisting of comprising a polypeptide comprising the entire or essentially the entire protein S binding site in C4b-binding protein (C4BP), and a polypeptide having essentially the same protein S binding properties as C4BP comprising an amino acid sequence homologous or analogous to the protein S binding site of the C4BP molecule, the ligand being capable of binding a free protein S at a first site;
 - a reagent <u>comprising an antibody or a fragment thereof</u> that <u>specifically</u> binds protein S at a site distinct from the first site; and
 - an indicating means indicator capable of producing a detectable signal indicative of the formation of a complex between free protein S, the ligand, and the reagent.
- 21. (Previously presented) The kit of claim 20, wherein the ligand is operatively linked to a carrier.
- 22. (Previously presented) The kit of claim 21, wherein the carrier is a microtiter plate.
- 23-30. (Canceled)
- 31. (Currently amended) A kit for purifying free protein S from an aqueous solution, the kit comprising:

U.S. Serial No.: 10/037,296

Attorney Docket No.: INL-054DV

Page 4 of 14

a ligand selected from a group consisting of a polypeptide comprising the entire or essentially the

entire protein S binding site in C4b-binding protein (C4BP), and a polypeptide having essentially

the same protein S binding properties as C4BP comprising an amino acid sequence homologous

or analogous to the-protein S binding site of the C4BP molecule; and

at least one further reagent for purification of protein S, wherein the at least one further reagent

is capable of releasing protein S from a complex comprising free protein S and the ligand.

32. (Canceled)

33. (Canceled)

34. (Canceled)

35. (Currently amended) The kit of claim 2050, wherein the antibody is a monoclonal antibody.

36. (Currently amended) The kit of claim 2050, wherein the antibody is a polyclonal antibody.

37. (Previously presented) The kit of claim 20, wherein the ligand comprises the extreme N-

terminal SCR module of the beta-chain of the C4BP molecule.

38. (Currently amended) The kit of claim 20, wherein the indicating means indicator is selected

from the group consisting of a chromogenic label, a fluorescent label, a chemiluminogenic label,

an enzymatic label, and a radioactive label.

39. (Currently amended) The kit of claim 20, wherein the indicating means indicator comprises

horseradish peroxidase.

40. (Currently amended) The kit of claim 20, further comprising a substrate for visualizing the

detectable signal.

41. (Currently amended) The kit of claim 20, wherein the indicating means indicator is

operatively linked to, or incorporated into, the ligand.

U.S. Serial No.: 10/037,296

Attorney Docket No.: INL-054DV

Page 5 of 14

42. (Currently amended) The kit of claim 20, wherein the indicating means indicator is operatively linked to, or incorporated into, the reagent.

- 43. (Canceled)
- 44. (Previously presented) The kit of claim 31, wherein the ligand comprises the extreme Nterminal SCR module of the beta-chain of the C4BP molecule.
- 45. (Previously presented) The kit of claim 31, wherein the ligand is bound to a carrier.
- 46. (Canceled)
- 47. (Canceled)
- 48. (Canceled)
- 49. (Canceled)
- 50. (Currently amended) The kit of claim 21, wherein the carrier is of a material selected from the group consisting of cross-linked dextran, agarose, polystyrene, polyvinyl chloride, crosslinked polyacrylamide, nitrocellulose, and nylon.
- 51. (Currently amended) The kit of claim 45, wherein the carrier is of a material selected from the group consisting of cross-linked dextran, agarose, polystyrene, polyvinyl chloride, crosslinked polyacrylamide, nitrocellulose, and nylon.
- 52. (Previously presented) The kit of claim 20 further comprising calcium ion.
- 53. (Previously presented) The kit of claim 20, wherein the ligand is synthetic or recombinant.
- 54. (Previously presented) The kit of claim 53, wherein the ligand comprises multiple subunits, each of which contains a protein S binding site.

U.S. Serial No.: 10/037,296

Attorney Docket No.: INL-054DV

Page 6 of 14

55. (Previously presented) The kit of claim 20, wherein the ligand is derived from C4BP isolated from blood.

- 56. (Previously presented) The kit of claim 55, wherein the ligand is derived from C4BP through enzymatic cleavage.
- 57. (Currently amended) The kit of claim-49 20, wherein the indicating means indicator is operatively linked to, or incorporated into, the antibody or fragment thereof.
- 58. (Previously presented) The kit of claim 31, wherein the ligand comprises multiple subunits, each of which contains a protein S binding site.
- 59. (New) A kit for assaying free protein S, the kit comprising:
 - a ligand comprising a polypeptide having essentially the same protein S binding properties as C4b-binding protein (C4BP) comprising an amino acid sequence homologous or analogous to the protein S binding site of the C4BP molecule, the ligand being capable of binding a free protein S at a first site;
 - a reagent comprising an antibody or a fragment thereof that specifically binds protein S at a site distinct from the first site; and
 - an indicator capable of producing a detectable signal indicative of the formation of a complex between free protein S, the ligand, and the reagent.
- 60. (New) The kit of claim 59, wherein the ligand is operatively linked to a carrier.
- 61. (New) The kit of claim 60, wherein the carrier is a microtiter plate.
- 62. (New) The kit of claim 59, wherein the antibody is a monoclonal antibody.
- 63. (New) The kit of claim 59, wherein the antibody is a polyclonal antibody.

U.S. Serial No.: 10/037,296

Attorney Docket No.: INL-054DV

Page 7 of 14

64. (New) The kit of claim 59, wherein the ligand comprises the extreme N-terminal SCR

module of the beta-chain of the C4BP molecule.

65. (New) The kit of claim 59, wherein the indicator is selected from the group consisting of a

chromogenic label, a fluorescent label, a chemiluminogenic label, an enzymatic label, and a

radioactive label.

66. (New) The kit of claim 59, wherein the indicator comprises horseradish peroxidase.

67. (New) The kit of claim 59 further comprising a substrate for visualizing the detectable

signal.

68. (New) The kit of claim 59, wherein the indicator is operatively linked to, or incorporated

into, the ligand.

69. (New) The kit of claim 59, wherein the indicator is operatively linked to, or incorporated

into, the reagent.

70. (New) The kit of claim 60, wherein the carrier is of a material selected from the group

consisting of cross-linked dextran, agarose, polystyrene, polyvinyl chloride, cross-linked

polyacrylamide, nitrocellulose, and nylon.

71. (New) The kit of claim 59 further comprising calcium ion.

72. (New) The kit of claim 59, wherein the ligand is synthetic or recombinant.

73. (New) The kit of claim 72, wherein the ligand comprises multiple subunits, each of which

contains a protein S binding site.

74. (New) The kit of claim 59, wherein the ligand is derived from C4BP isolated from blood.

75. (New) The kit of claim 74, wherein the ligand is derived from C4BP through enzymatic

cleavage.

Amendment and Response U.S. Serial No.: 10/037,296

Attorney Docket No.: INL-054DV

Page 8 of 14

76. (New) The kit of claim 59, wherein the indicator is operatively linked to, or incorporated into, the antibody or fragment thereof.

- 77. (New) The kit of claim 59, wherein the ligand is operatively linked to a matrix.
- 78. (New) The kit of claim 20, wherein the ligand is operatively linked to a matrix.
- 79. (New) The kit of claim 31, wherein the ligand is bound to a matrix.